Page last updated: 2024-12-06

bis(trichloromethyl)sulfone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(trichloromethyl)sulfone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62478
CHEMBL ID3561446
SCHEMBL ID21383
MeSH IDM0148880

Synonyms (42)

Synonym
trichloromethylsulfone
nsc21713
bis(trichloromethyl) sulfone
sulfone, bis(trichloromethyl)
nsc-21713
chlorosulfona
hexachlorodimethyl sulfone
3064-70-8
clorosulfona
methane, sulfonylbis[trichloro-
n 1386
methane, sulfonylbis(trichloro-
n-1386 biocide
caswell no. 104
slimicide e
hsdb 7126
bis(trichloromethyl)sulfone
ccris 809
nsc 21713
epa pesticide chemical code 035601
bis(trichloromethyl) sulphone
einecs 221-310-4
brn 1783352
trichloro(trichloromethylsulfonyl)methane
FT-0669131
4-03-00-00285 (beilstein handbook reference)
ptz0qe9824 ,
methane, 1,1'-sulfonylbis(1,1,1-trichloro-
unii-ptz0qe9824
bis(trichloromethyl)sulphone
bis(trichloromethyl)sulfone [hsdb]
SCHEMBL21383
dtxcid1012331
tox21_303827
cas-3064-70-8
NCGC00357286-01
dtxsid3032331 ,
CHEMBL3561446
trichloromethyl sulfone, aldrichcpr
bis-(trichloromethyl)sulfone
methane, 1,1'-sulfonylbis[1,1,1-trichloro-
Q27286750

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The oral LD50 for bis(trichloromethyl) sulfone (N-1386 Biocide) in male rats was 691 mg/kg."( Anticholinesterase effect and toxicity of bis(trichloromethyl) sulfone (N-1386 Biocide) in rats.
Castles, TR; Sprague, GL, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency20.00480.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency37.71163.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency9.54820.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency48.96620.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency48.96620.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency2.80330.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency18.65820.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency39.59780.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.15000.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency10.71320.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency34.70270.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency62.93100.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.30600.000229.305416,493.5996AID1259244; AID1259248
thyroid stimulating hormone receptorHomo sapiens (human)Potency61.13060.001628.015177.1139AID1259385; AID1259395
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency33.82600.154917.870243.6557AID1346877
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency54.94100.057821.109761.2679AID1159526
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.30600.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.30600.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.27 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]